Inspection reports obtained by ABC News show a series of quality control issues. Even as shots of the Johnson & Johnson COVID-19 vaccine resume across the country following a recent ...
A new day has dawned in the fight against the U.S. opioid epidemic after the FDA approved the first over-the-counter naloxone product. And the gold medal goes to Emergent BioSolutions. Wednesday, the ...
Emergent BioSolutions, already flush with products against public health threats like anthrax attacks and opioid overdoses, is expanding its arsenal of medical countermeasures by scooping up global ...
Quality control errors led millions of potential vaccines to be ruined. For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned. Standing ...
Emergent hits $15 million in ARR in 90 days, becomes one of the fastest growing AI start-ups; its platform is the world's first agentic vibe-coding platform that builds production-ready applications ...
Emergent BioSolutions faces declining revenues, increasing competition, and limited growth potential, leading to a sell rating due to poor risk-reward profile. NARCAN, their main revenue generator, is ...
When contract-manufacturer Emergent BioSolutions contaminated at least 15 million doses of Johnson & Johnson’s COVID-19 vaccine and millions more doses of AstraZeneca’s vaccine at its Baltimore ...
The market for Emergent BioSolutions Inc.'s (NYSE:EBS) stock was strong after it released a healthy earnings report last week. However, we think that shareholders should be cautious as we found some ...
Tom spent 20 years running his own contracting company, working as a building mechanic and operating as a carpenter. Now he creates solar, home security, moving and home warranty content content for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback